Biotech M&A · Q1 2026 Report
A summary of biotech and biopharma acquisitions announced in Q1 2026 — covering deal value, structure, therapeutic area, and what the tape is signalling about strategic priorities.
The quarter closed with 16 control transactions spanning public and private targets, with an acceleration in pace and deal size through March. Buyers are paying for approved products, near-commercial assets, and clear strategic platform fit — not broad early-stage optionality alone.
Report date: 31 March 2026
Q1 2026 snapshot
|
Total deals
16
Q1 2026
|
Disclosed value
~$38B
Total deal value
|
|
Largest deal
$7.8B
Arcellx & Centessa (tied)
|
Public targets
7 of 16
9 private targets
|
Market activity
Deal value by month (US$B)
|
$4.6B
|
$11.2B
|
$28.3B
|
| January | February | March |
Therapeutic area breakdown
|
Immunology dominates by deal count. Two of Q1's three largest tickets were in oncology/hematology (Arcellx, Terns).
|
Top acquirers by total deal value (US$B)
| Eli Lilly | $11.4B | 3 deals |
| Gilead | $10.0B | 2 deals |
| Merck | $6.7B | 1 deal |
| Biogen | $5.6B | 1 deal |
| GSK | $3.2B | 2 deals |
| Servier | $2.5B | 1 deal |
| Novartis | $2.0B | 1 deal |
| Otsuka | $1.2B | 1 deal |
Lilly leads Q1 capital deployed with $11.4B across three deals (Ventyx, Orna, Centessa) targeting oral inflammation, in vivo cell therapy, and sleep medicine. Gilead's $10B across Arcellx and Ouro reflects a parallel pivot into CAR-T and autoimmune disease. Values shown are total disclosed deal values including contingent milestones.
Key themes
1 | Immunology is the defining battleground |
Seven of 16 deals touch immunology in some form — allergy (RAPT, Excellergy), complement biology (Apellis), autoimmune (Ouro, Orna), and oral inflammation (Ventyx). Buyers are not acquiring point solutions; they are building platforms capable of expanding into adjacent indications. The implicit bet is that immunology will be the post-incretin growth story for large-cap pharma.
2 | Lilly and Gilead account for more than half of all capital deployed |
Together they put to work over $21B across five transactions — using M&A not as opportunistic pipeline fill but as deliberate portfolio repositioning. Gilead is remaking itself around cell therapy and autoimmune disease. Lilly is building the next chapter beyond GLP-1 with platforms in inflammation, cell therapy, and CNS.
3 | March surge: half the quarter landed in one month |
January was quiet ($4.6B), February picked up ($11.2B), and March accounted for an estimated $28B including two $7.8B mega-deals on the same day. The pace compression — eight deals in March alone — suggests deal teams were racing to close before Q2 macro headwinds (including tariff uncertainty) tightened conditions.
4 | Private targets outnumber public, 9 to 7 |
The majority of deal count came from private acquisitions. Large-cap buyers are increasingly willing to underwrite multi-billion bets on private, early-to-mid stage assets — accepting more binary clinical risk in exchange for getting ahead of competitive public-market auctions. Orna, Ouro, Excellergy, and Transcend are all examples of this dynamic.
5 | Premium dispersion on public deals |
Premiums ranged from 2% (Ventyx) to ~140% (Apellis). Terns was acquired at just ~6% over its prior close for $6.7B, suggesting the stock had already re-rated on deal speculation or that Merck held firm on pricing. Apellis's 140% premium reflects a deeply discounted starting point, not necessarily excess generosity.
6 | Selective, not indiscriminate, M&A |
The tape is not showing a broad "buy everything" environment. Buyers are consistently paying for approved products, near-commercial assets, or platforms with a clear strategic lane — and passing on pure early-stage optionality. CVR structures (Biogen/Apellis, Gilead/Arcellx, Centessa) are also being used more actively to bridge valuation gaps on milestone-dependent assets.
All Q1 2026 transactions
Methodology: Focuses on company-level control transactions announced or first publicly disclosed in Q1 2026 across biotech/biopharma. Headline values shown on the basis most prominently disclosed (equity value, upfront + milestones, or per-share cash + CVR). Rumour-only situations excluded. Source data: BioBucks M&A Tracker 2026, updated 31 March 2026.